Pravachol DTC Ads Promote NCEP Guidelines, Reps Focus On High Prescribers
Executive Summary
Bristol-Myers Squibb has begun a DTC advertising campaign for its cholesterol-lowering HMG CoA reductase inhibitor Pravachol that will focus on the recently released National Cholesterol Education Program guidelines.
You may also be interested in...
Andrx Altocor Will Test “Guerilla” Marketing In Cholesterol Market
Andrx is confident that it can establish the cholesterol agent Altocor with a sales force of less than 300
Andrx Altocor Will Test “Guerilla” Marketing In Cholesterol Market
Andrx is confident that it can establish the cholesterol agent Altocor with a sales force of less than 300
Mylan paclitaxel
Second generic version of Bristol-Myers Squibb's Taxol (paclitaxel) enters market following FDA's July 23 approval of Mylan's ANDA. The approval covers 30 mg/5 mL, 100 mg/16.7 mL and 300 mg/50 mL vials. Mylan's approval was delayed beyond the expiration of Ivax' 180-day generic exclusivity April 22, due to amendments pending at FDA to include the 100 mg and 300 mg vials (which were not in the original application), and to approve a second paclitaxel raw material source, Mylan said. The company expects the second source in China to allow it to expand its capacity from 35 kg of raw material to 64 kg